UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
Read more on Pittsburgh Business Times.
Pittsburgh Business Times: UPMC Enterprises invests in prescription analytics company RxAnte
Related Resources
More Resources
04.23.19
Controlling CMS Star Ratings – Part II
Blog Post
In our last blog post, we began to discuss how MAPD plans, amid so much market uncertainty, have the potential to not just control but improve their Star Ratings. Here, we build on that blog to discuss identifying the right members to reach and refining intervention methods to meet those members’ individual needs.
04.16.19
Controlling CMS Star Ratings – Part I
Blog Post
MAPD plan leaders face a series of growing challenges, ranging from rising cut points to evolving CMS rules to intensifying spending pressures. One of the biggest challenges, however, is within a plan’s control: CMS Star Ratings.
04.09.19
UPDATE: CMS 2020 Methodological Changes Impacting MA Plans
Blog Post
At the end of January 2019, CMS released notice of impending changes to the methodology of Medicare Advantage (MA) “Capitation Rates and Part D Payment Policies.” There are a few primary changes that MA Part D (MAPD) plans will want to know about. Here’s the summary, and we’ve added some notes for places RxAnte can help.